Levenue Oral Solution contains Levetiracetam 100 mg per milliliter and is indicated as an adjunctive therapy for the treatment of partial-onset seizures, myoclonic seizures, and primary generalized tonic-clonic seizures in patients with epilepsy. Levetiracetam, a pyrrolidone derivative, exerts its antiepileptic effects through modulation of synaptic neurotransmitter release via binding to the synaptic vesicle protein SV2A, thereby reducing neuronal excitability. The oral solution formulation allows for flexible dosing, particularly beneficial for pediatric and geriatric populations or patients with swallowing difficulties. Levenue Oral Solution is rapidly absorbed with a bioavailability approaching 100%, and it is minimally metabolized by the liver, reducing the potential for drug-drug interactions. The medication is primarily excreted unchanged by the kidneys; therefore, dose adjustments may be necessary in patients with renal impairment. Common adverse effects include somnolence, dizziness, fatigue, and behavioral symptoms such as irritability or agitation. Caution is advised in patients with a history of psychiatric disorders. Levenue Oral Solution should be administered under medical supervision with regular monitoring to optimize therapeutic outcomes and minimize adverse effects. It is essential to adhere to prescribed dosing schedules and not to discontinue therapy abruptly to prevent seizure exacerbation.